Modulation of CD8 + T cell responses to AAV vectors with IgG-derived MHC class II epitopes

Molecular Therapy

Volumn 21, Issue 9, 2013, Pages 1727-1737

  Hui, Daniel J ^a   Basner Tschakarjan, Etiena ^a   Chen, Yifeng ^a,b   Davidson, Robert J ^a   Buchlis, George ^a,c   Yazicioglu, Mustafa ^a   Pien, Gary C ^a   Finn, Jonathan D ^a   Haurigot, Virginia ^a   Tai, Alex ^a   Scott, David W ^d   Cousens, Leslie P ^e   Zhou, Shangzhen ^a   De Groot, Anne S ^e,f   Mingozzi, Federico ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^e EpiVax Inc   (United States)

^f UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CD4 ANTIGEN; IMMUNOGLOBULIN G; INTERLEUKIN 2 RECEPTOR ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PARVOVIRUS VECTOR; TRANSCRIPTION FACTOR FOXP3; VIRUS ANTIGEN; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL CONTACT; CELL KILLING; CELLULAR IMMUNITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOREACTIVITY; IN VITRO STUDY; INFLAMMATORY INFILTRATE; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; REGULATORY T LYMPHOCYTE; SPLEEN; TARGET CELL; VIRUS CAPSID;

ADENO-ASSOCIATED VIRUS; MIRIDAE;

ANIMALS; ANTIGENS, VIRAL; CAPSID; CAPSID PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DEPENDOVIRUS; EPITOPES, T-LYMPHOCYTE; GENETIC THERAPY; GENETIC VECTORS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOGLOBULIN G; MALE; MICE; MICE, INBRED C57BL; SPLEEN; T-LYMPHOCYTES, REGULATORY;

EID: 84883741462     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.166     Document Type: Article

References (49)

1. Mingozzi, F and High, KA (2011). Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 12: 341-355.
2. Mingozzi, F and High, KA (2011). Immune responses to AAV in clinical trials. Curr Gene Ther 11: 321-330.
3. Manno, CS, Pierce, GF, Arruda, VR, Glader, B, Ragni, M, Rasko, JJ et al. (2006). Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12: 342-347. (Pubitemid 43355084)
4. Mingozzi, F, Maus, MV, Hui, DJ, Sabatino, DE, Murphy, SL, Rasko, JE et al. (2007). CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med 13: 419-422. (Pubitemid 46559826)
5. Nathwani, AC, Tuddenham, EG, Rangarajan, S, Rosales, C, McIntosh, J, Linch, DC et al. (2011). Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365: 2357-2365.
6. Muzyczka, N, and Berns, KI (2001). Parvoviridae: the viruses and their replication. Lippincott, Williams and Wilkins: Philadelphia.
7. Finn, JD (2010). Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction. Mol Ther 18: 135-142.
8. Pien, GC, Basner-Tschakarjan, E, Hui, DJ, Mentlik, AN, Finn, JD, Hasbrouck, NC et al. (2009). Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors. J Clin Invest 119: 1688-1695.
9. Zhong, L, Li, B, Mah, CS, Govindasamy, L, Agbandje-McKenna, M, Cooper, M et al. (2008). Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci USA 105: 7827-7832. (Pubitemid 351872723)
10. Calcedo, R, Morizono, H, Wang, L, McCarter, R, He, J, Jones, D et al. (2011). Adenoassociated virus antibody profiles in newborns, children, and adolescents. Clin Vaccine Immunol 18: 1586-1588.
11. Li, C (2011). Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia. Gene Ther 18: 288-294.
12. Veron, P, Leborgne, C, Monteilhet, V, Boutin, S, Martin, S, Moullier, P et al. (2012). Humoral and cellular capsid-specific immune responses to adeno-associated virus type 1 in randomized healthy donors. J Immunol 188: 6418-6424.
13. Jiang, H, Couto, LB, Patarroyo-White, S, Liu, T, Nagy, D, Vargas, JA et al. (2006). Effects of transient immunosuppression on adenoassociated, virus-mediated, liverdirected gene transfer in rhesus macaques and implications for human gene therapy. Blood 108: 3321-3328.
14. Mingozzi, F, Meulenberg, JJ, Hui, DJ, Basner-Tschakarjan, E, Hasbrouck, NC, Edmonson, SA et al. (2009). AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood 114: 2077-2086.
15. Peng, B, Ye, P, Rawlings, DJ, Ochs, HD and Miao, CH (2009). Anti-CD3 antibodies modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy. Blood 114: 4373-4382.
16. Safinia, N, Leech, J, Hernandez-Fuentes, M, Lechler, R and Lombardi, G (2013). Promoting transplantation tolerance; adoptive regulatory T cell therapy. Clin Exp Immunol 172: 158-168.
17. Battaglia, M and Roncarolo, MG (2011). Immune intervention with T regulatory cells: past lessons and future perspectives for type 1 diabetes. Semin Immunol 23: 182-194.
18. Vignali, DA, Collison, LW and Workman, CJ (2008). How regulatory T cells work. Nat Rev Immunol 8: 523-532.
19. Shevach, EM (2009). Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 30: 636-645.
20. De Groot, AS, Moise, L, McMurry, JA, Wambre, E, Van Overtvelt, L, Moingeon, P et al. (2008). Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". Blood 112: 3303-3311.
21. Cousens, LP, Mingozzi, F, van der Marel, S, Su, Y, Garman, R, Ferreira, V et al. (2012). Teaching tolerance: New approaches to enzyme replacement therapy for Pompe disease. Hum Vaccin Immunother 8: 1459-1464.
22. van der Marel, S, Majowicz, A, Kwikkers, K, van Logtenstein, R, te Velde, AA, De Groot, AS et al. (2012). Adeno-associated virus mediated delivery of Tregitope 167 ameliorates experimental colitis. World J Gastroenterol 18: 4288-4299.
23. Cousens, LP, Najafian, N, Mingozzi, F, Elyaman, W, Mazer, B, Moise, L et al. (2013). In vitro and in vivo studies of IgG-derived Treg epitopes (Tregitopes): a promising new tool for tolerance induction and treatment of autoimmunity. J Clin Immunol 33 Suppl 1: S43-S49.
24. Cousens, LP, Najafian, N, Mingozzi, F, Elyaman, W, Mazer, B, Moise, L et al. (2013). In vitro and in vivo studies of IgG-derived Treg epitopes (Tregitopes): a promising new tool for tolerance induction and treatment of autoimmunity. J Clin Immunol 33 Suppl 1: S43-S49.
25. Cohen, T, Moise, L, Ardito, M, Martin, W and De Groot, AS (2010). A method for individualizing the prediction of immunogenicity of protein vaccines and biologic therapeutics: individualized T cell epitope measure (iTEM). J Biomed Biotechnol 2010 (doi:10.1155/2010/961752).
26. Sabatino, DE, Mingozzi, F, Hui, DJ, Chen, H, Colosi, P, Ertl, HC et al. (2005). Identification of mouse AAV capsid-specific CD8+ T cell epitopes. Mol Ther 12: 1023-1033. (Pubitemid 41723036)
27. Margaritis, P, Arruda, VR, Aljamali, M, Camire, RM, Schlachterman, A and High, KA (2004). Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VII. J Clin Invest 113: 1025-1031. (Pubitemid 38544124)
28. Velazquez, VM, Bowen, DG and Walker, CM (2009). Silencing of T lymphocytes by antigen-driven programmed death in recombinant adeno-associated virus vectormediated gene therapy. Blood 113: 538-545.
29. Tang, Q, Bluestone, JA and Kang, SM (2012). CD4(+)Foxp3(+) regulatory T cell therapy in transplantation. J Mol Cell Biol 4: 11-21.
30. Gross, DA, Leboeuf, M, Gjata, B, Danos, O and Davoust, J (2003). CD4+CD25+ regulatory T cells inhibit immune-mediated transgene rejection. Blood 102: 4326-4328. (Pubitemid 37494091)
31. Amarilyo, G, Hahn, B and La Cava, A (2012). Preclinical studies with synthetic peptides in systemic lupus erythematosus. Front Biosci 17: 1940-1947.
32. Sthoeger, ZM, Sharabi, A, Molad, Y, Asher, I, Zinger, H, Dayan, M et al. (2009). Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression. J Autoimmun 33: 77-82.
33. Ephrem, A, Chamat, S, Miquel, C, Fisson, S, Mouthon, L, Caligiuri, G et al. (2008). Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 111: 715-722.
34. Li, C, Hirsch, M, Asokan, A, Zeithaml, B, Ma, H, Kafri, T et al. (2007). Adenoassociated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo. J Virol 81: 7540-7547. (Pubitemid 47047840)
35. Li, H, Murphy, SL, Giles-Davis, W, Edmonson, S, Xiang, Z, Li, Y et al. (2007). Preexisting AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes. Mol Ther 15: 792-800. (Pubitemid 46432000)
36. Li, H, Tuyishime, S, Wu, TL, Giles-Davis, W, Zhou, D, Xiao, W et al. (2011). Adenoassociated virus vectors serotype 2 induce prolonged proliferation of capsid-specific CD8+ T cells in mice. Mol Ther 19: 536-546.
37. Wang, L, Figueredo, J, Calcedo, R, Lin, J and Wilson, JM (2007). Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets. Hum Gene Ther 18: 185-194. (Pubitemid 46626458)
38. Miller, RG (1980). An immunological suppressor cell inactivating cytotoxic T-lymphocyte precursor cells recognizing it. Nature 287: 544-546. (Pubitemid 11232853)
39. Reich-Zeliger, S, Eidelstein, Y, Hagin, D, Antebi, YE, Seger, R and Reisner, Y (2010). Deletion of alloreactive T cells by veto cytotoxic T lymphocytes is mediated through extracellular signal-regulated kinase phosphorylation. Transplantation 90: 380-386.
40. Nguyen, P and Geiger, TL (2010). Induction of B-cell immune tolerance by antigenmodified cytotoxic T lymphocytes. Transplantation 89: 667-676.
41. Yamaguchi, T, Wing, JB and Sakaguchi, S (2011). Two modes of immune suppression by Foxp3(+) regulatory T cells under inflammatory or non-inflammatory conditions. Semin Immunol 23: 424-430.
42. Wang, L, Cao, O, Swalm, B, Dobrzynski, E, Mingozzi, F and Herzog, RW (2005). Major role of local immune responses in antibody formation to factor IX in AAV gene transfer. Gene Ther 12: 1453-1464. (Pubitemid 41486134)
43. Saadoun, D, Rosenzwajg, M, Joly, F, Six, A, Carrat, F, Thibault, V et al. (2011). Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 365: 2067-2077.
44. Gao, GP, Alvira, MR, Wang, L, Calcedo, R, Johnston, J and Wilson, JM (2002). Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 99: 11854-11859. (Pubitemid 34994488)
45. Mingozzi, F, Liu, YL, Dobrzynski, E, Kaufhold, A, Liu, JH, Wang, Y et al. (2003). Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest 111: 1347-1356. (Pubitemid 36554705)
46. Warrington, KH Jr, Gorbatyuk, OS, Harrison, JK, Opie, SR, Zolotukhin, S and Muzyczka, N (2004). Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus. J Virol 78: 6595-6609. (Pubitemid 38715956)
47. Martino, AT, Basner-Tschakarjan, E, Markusic, DM, Finn, JD, Hinderer, C, Zhou, S et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121: 2224-2233.
48. Chen, YH, Chang, M and Davidson, BL (2009). Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy. Nat Med 15: 1215-1218.
49. Schanen, BC, De Groot, AS, Moise, L, Ardito, M, McClaine, E, Martin, W et al. (2011). Coupling sensitive in vitro and in silico techniques to assess cross-reactive CD4(+) T cells against the swine-origin H1N1 influenza virus. Vaccine 29: 3299-3309.